Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
R1507 (RO4858696) plus Tarceva in NSCLC patients resistant to erlotinib
2008-001762-85Phase 2Completed
- Sponsor
- Roche
- Start
- Sep 2008
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of erlotinib and teprotumumab in non-small cell lung cancer (NSCLC), sponsored by Roche. Primary endpoint: Progression-free survival rate at 12 weeks. Started Sep 2008; status: completed.
02
Drugs
erlotinibteprotumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2008-001762-85.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-001762-85.